Details of Disease

General Information of Disease (ID: DISEG262)

• Disease Name: Postpoliomyelitis syndrome
• Synonyms: post-polio muscular atrophy; post-polio sequelae; post polio syndrome; polio late effects; post-poliomyelitic syndrome; postpoliomyelitic syndrome; postpoliomyelitis syndrome; Post Polio Syndrome; postpolio sequelae; postpolio syndrome; postpoliomyelitis sequelae
• Definition: Postpoliomyelitis syndrome (PPS) is a neurologic disorder characterized by the development of new neuromuscular symptoms such as progressive muscular weakness or abnormal muscle fatigability occurring in survivors of the acute paralytic form of poliomyelitis, 15-40 years after recovery from the disease, and that is unexplained by other medical causes. Other manifestations that can occur gradually include generalized fatigue, muscle atrophy, muscle and joint pain, intolerance to cold, and difficulties sleeping, swallowing or breathing.
• Disease Hierarchy:
  DISANFJN: Poliomyelitis
  DISEG262: Postpoliomyelitis syndrome
• Disease Identifiers:
  MONDO ID: MONDO_0017416
  MESH ID: D016262
  UMLS CUI: C0080040
  MedGen ID: 36363
  Orphanet ID: 2942
  SNOMED CT ID: 31097004

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Armodafinil	DMGB035	Approved	Small molecular drug	[1]
Levacecarnine hci	DMJBOCR	Approved	Small molecular drug	[2]
Modafinil	DMYILBE	Approved	Small molecular drug	[3]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Armodafinil FDA Label
• [2] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [3] Modafinil FDA Label